GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche Sequencing Solution of Roche is focused on developing novel technologies and products to support innovation in clinical research applications. Part of Roche Sequencing Solutions, the Harmony® prenatal test is a non-invasive screening test for pregnant women that can be used as early as 10 weeks of pregnancy. By evaluating fetal cell-free DNA found in maternal blood, including accurate measurement of the fetal fraction of cfDNA, the test assesses the probability of Trisomy 21 (Down syndrome) and other common fetal chromosomal conditions. The results are intended for prenatal screening and are not intended to be the sole basis for diagnosis. The Harmony® prenatal test has been used to guide clinical care in over 1,400,000 pregnancies worldwide. For more information, visit www.harmonytest.com.
PerkinElmer is a global company focused on improving the health and safety of people and their environment. Within the field of fetal and maternal healthcare, PerkinElmer offers complete screening solutions including instrumentation, reagents and risk calculation software for early detection of pregnancy related anomalies. Annually, more than 10 million prenatal risk assessments are made on the basis of PerkinElmer tests.
PerkinElmer was chosen as the principal screening partner for ASPRE. Throughout the study, the PerkinElmer DELFIA® Xpress PlGF 1-2-3TM assay was used as an aid in screening for pre-eclampsia in conjunction with maternal history, mean arterial blood pressure (MAP) measurement, and uAD (Uterine Artery Doppler). ASPRE results were published in June 2017 and demonstrated that early screening helps significantly reduce the incidence of preterm pre-eclampsia.
PerkinElmer is developing the Vanadis® NIPT system which is an automated non-sequencing, non-PCR based solution for cfDNA analysis. PerkinElmer will in the future offer an easy to use, cost-effective, high-throughput screening test to help facilitate wider access to non-invasive prenatal testing for pregnant women.
Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.
CANON MEDICAL SYSTEMS
Canon Medical offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound and MRI, across the globe. As of December 2016, Canon Medical became a member of the Canon Group. In line with our continued Made For life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features.
At Canon Medical we work hand in hand with our partners – our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life.
STANDARD PLUS SPONSORS
As one of the leading global providers of medical devices and solutions, Mindray is committed to sharing medical technologies with the world and dedicated to innovation in Medical Imaging System. Headquartered in China, Mindray possesses a sound global R&D, marketing and service network with subsidiaries and branch offices in 32 countries.
Inspired by the needs of customers, Mindray always adopts advanced technologies and transforms them into accessible innovation, bringing healthcare within reach. Today, Mindray’s products and services can be found in healthcare facilities in over 190 countries and regions.
Thermo Scientific B•R•A•H•M•S Biomarkers investigates, develops and manufactures novel diagnostic testing procedures to improve early diagnosis and treatment of life threatening diseases. With high-quality immunodiagnostic tests for sepsis, cardiovascular, pulmonary, and cancer disorders as well as prenatal screening we contribute to the creation of a healthier future – to the greatest advantage for medical professionals and patients.In future simple and economic blood tests will be of great importance for an early detection and successful treatment of diseases. With our know-how and technologies we are confident to play an active role in this future: Our products provide important information to clinicians and laboratories in more than 130 countries worldwide, supporting their clinically and economically relevant decisions.
The Gold Standard in Prenatal Screening on KRYPTOR Systems is expanded by adding sFlt-1 for diagnosis of pre-eclampsia Together with the B•R•A•H•M•S PlGF KRYPTOR assay, B•R•A•H•M•S sFlt-1 KRYPTOR improves the diagnosis of pre-eclampsia in 2nd/3rd trimester of pregnancy. The ratio sFlt-1/PlGF is a predictor of adverse outcome in women who develop pre-eclampsia and can advise for a closer monitoring and special care. The latest addition of the sFlt-1 assay as well as the extension of indication for PlGF highly complements Thermo Fisher’s already existing Prenatal Screening portfolio (PAPP-A, Free βhCG, AFP, hCG+β, Fast Screen pre I plus software). Ongoing research and development activities will further contribute to the PNS product range. All B•R•A•H•M•S KRYPTOR platforms are FMF approved and in routine use since 1999,providing reliable results and meeting the highest quality standards of FMF.
Philips is one of the world’s leading technology companies, with a long history of practical innovation and visionary design. In healthcare, we are committed to understanding the human and technological needs of patients and caregivers. We believe this understanding will help us deliver solutions that not only enable more confident diagnoses and more efficient delivery of care, but also improve the overall experience of care. We offer equipment, software, and services for imaging, patient monitoring, resuscitation and much more. Visit us at booth to learn more. People focused. Healthcare simplified.
201 Industrial Road, Suite 410, San Carlos, CA 94070
Natera® is a worldwide genetic testing and diagnostics company that’s changing how doctors and patients manage genetic disease. Our team includes scientists, biostatisticians, researchers, and talented laboratory professionals from around the globe. Natera develops and commercializes non-invasive methods for analyzing DNA. We operate a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California, and offer a host of proprietary genetic testing services. Our portfolio includes a wide range of tests from preimplantation genetic diagnosis (PGD) for IVF to breakthrough advances in the field of non-invasive prenatal testing (NIPT). Recently, Natera moved beyond chromosomal aneuploidy to screen noninvasively for de novo single gene mutations with its Vistara test. Vistara fits in with Natera's extensive portfolio of reproductive health products, enabling the company to engage with patients and physicians from pre-pregnancy through birth. Natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the industry.
Genoma Swiss Biotechnology
Chemin des Aulx 12 1228 Plan-les-Ouates, Geneva, Switzerland
Genoma Swiss Biotechnology is a Swiss company leader in genomics for Precision Medicine which owns one of the largest laboratories for clinical diagnostics in Europe. Its exclusive next generation genetic tests are performed following the highest quality standards. At Genoma Swiss Biotechnology our mission is to enable people to have a better knowledge about their own health and that of their baby by investing doctors and families with most relevant early actionable genetic information to take appropriate medical decisions. Genoma Swiss Biotechnology is part of Esperite Group.
Genoma Swiss Biotechnology is part of ESPERITE is a diversified biotech global group leader in regenerative and precision medicine. Established in 2000, the holding group is headquartered in the Netherlands, listed at Euronext Amsterdam and Paris and operational in over 30 countries counting more than 200 employees. ESPERITE transforms the power of state-of-the-art technologies and scientific advancements into high quality products that bring the future of medicine to customers today at an affordable price.
NIPD Genetics is a European biotechnology company that designs, develops, and manufactures non-invasive genetic tests. NIPD Genetics was founded in 2010 as a spin-off from the Cyprus Institute of Neurology and Genetics to commercialize pioneering research work in the field of non-invasive prenatal diagnosis. NIPD Genetics leverages its proprietary genetic and bioinformatics methods to develop novel technologies for prediction and diagnosis of genetic disorders. NIPD Genetics provides the VERACITY non-invasive prenatal test for the detection of trisomies of chromosomes 21, 18, 13, aneuploidies of X and Y and microdeletions.
Premaitha Health is a UK molecular diagnostics company, the flagship product is the IONA® test which screens for Down’s, Edwards’ and Patau’s syndrome. It is safe, fast and accurate with results available in as little as 3 days and reduces the need for invasive tests and the associated stress and anxiety. The IONA® test is suitable for all singleton, twin pregnancies and for those conceived through surrogates or IVF. The IONA® test has a very low re-draw rate of <0.5% and can generate a valid result from a sample with as low as 2% fetal fraction, samples are analysed in the UK with results sent securely through the MyNIPT® portal.
We partner with healthcare providers around the globe to offer clear and actionable genetic results that help patients and their families Prepare for Life.
Test for carrier status with the Preparent® family of genetic carrier tests. Three panels evaluate carrier status for up to 200+ hereditary disorders impacting infancy or early childhood and include conditions recommended by ACOG.
Screen for chromosomal disorders with the Innatal® prenatal screen. Non-invasive cell-free DNA analysis assesses pregnancies for common chromosome aneuploidies, providing highly accurate results in singleton and multiple pregnancies.
Results are ready in 10 to 14 days.
Visit us at Booth 13 or at progenity.com.
Integrated Genetics is a leading provider of reproductive genetic testing services driven by its commitment to physicians and their patients. With the addition of Sequenom, a pioneer in the fast-growing area of non-invasive prenatal testing, Integrated Genetics can now offer physicians and patients more options for prenatal testing. We also offer the largest commercial genetic counseling network in the laboratory industry.
astraia software is based in Munich, Germany and was founded in 2000. The aim was to develop an independent database application that would cover all aspects of obstetrics and gynaecology to the highest medical standard.
Since then, astraia has established its position as market leader and pioneer in obstetric and gynaecological database applications. The company's success is due to a close working relationship with leading experts worldwide and highly flexible adaptation to market requirements . In many countries astraia is also represented by local sales partners to assure first class customer service. The astraia software solutions provide healthcare professionals with structured data entry screens that guide through the examination, making sure nothing is missed . All data(including measurements and images) is saved securely . It can be accessed any time for later reference or queried for studies and further analysis . Creating a complete and appealing report only takes a few mouse clicks .
Medisyn laboratory doctors’ cooperative was founded in Greece in 1995, aiming to provide pioneering, integrated and reliable services in Primary Health Care Sector. With a combined service experience of over twenty years, Medisyn owns 3 state of the art diagnostic laboratories in Athens, Thessaloniki and Crete.
In compliance with the most strict ISO certifications and accreditations (ISO 15189) and external quality control audits (ISO 17043), we carry out a vast array of hematology, clinical biochemistry, hormonal, culture, molecular biology, microbiology and microscopy tests on blood, cellular and all excretory system samples.
Our laboratory tests cover a wide range of clinical specialty areas, such as microbiology and infectious disease, fertility, prenatal diagnosis, endocrinology, cardiology, hematology, oncology, neurology, drug abuse, gastroenterology, pediatrics and genetics for laboratories, hospitals and specialty clinics.